回盛生物(300871.SZ): 泰地羅新原料及注射液獲二類新獸藥註冊證書
格隆匯1月27日丨回盛生物(300871.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經農業農村部審查,批准公司及全資子公司湖北迴盛生物科技有限公司、長沙施比龍動物藥業有限公司聯合其他單位共同申報的泰地羅新原料及注射液兩種獸藥產品為新獸藥,農業農村部於2021年1月26日公示核發了《新獸藥註冊證書》(農業農村部公吿第391號)事項;註冊分類均為二類。
泰地羅新是最新大環內酯類動物專用抗生素,其通過單劑量注射的方式對豬呼吸系統疾病進行防治,在獸醫臨牀上主要用於治療由胸膜肺炎放線桿菌、多殺性巴氏桿菌、支氣管敗血波氏桿菌及副豬嗜血桿菌引起的豬呼吸道感染。
泰地羅新具體優勢:泰地羅新對豬的呼吸道疾病具有十分明顯的治療效果,且藥效強於泰樂菌素、替米考星,氟苯尼考等,而且具備動物專用、用量少、一次給藥全程治療、超長的消除半衰期、生物利用度高、低毒、低殘留等眾多優點。
公司表示,該新獸藥證書的取得是公司持續重視科技創新、加大研發投入的結果,該產品是新一代廣譜高效、安全低毒的動物專用抗菌藥,是目前用於防治豬呼吸道疾病的重要產品,對提升公司市場競爭力、推動公司家畜呼吸道系統疾病戰略佈局的實施具有積極的促進作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.